Sorry, you need to enable JavaScript to visit this website.

Pandemics

Subject Hierarchy
Broader terms
Epidemics
Current term
Pandemics
Permalinks
APO URI

ADVERTISEMENT

Report

Improved wellbeing or distress? Measuring the impacts of participation in a COVID-19 survey on participant wellbeing


For many throughout the world, the COVID-19 pandemic has resulted in drastic changes to life and social circumstances through health concerns related to the fear of infection with coronavirus, the negative impact of physical distancing measures and economic upheaval. For these reasons, COVID-19-related research has the potential to cause distress and anxiety for participants.
Report

Short report: social isolation, loneliness and COVID-19


This short report presents key insights about those at risk of social isolation and loneliness from a literature review and descriptive analysis of the 2018 New Zealand General Social Survey. Specifically, insights are drawn about the effects this risk has on wellbeing and the likely impact of the COVID-19 Lockdown. This report is for government...
Briefing paper

Targeting support for rural communities in the COVID-19 recovery


No New Zealand region will escape the current economic downturn, but some rural communities will face bigger impacts than others. This publication looks at how to identify and target support at communities most affected by COVID-19.
Fact sheet

COVID-19 and the demographic distribution of health and economic risks


This fact sheet documents the demographic distribution of different health and economic risks across the Australian population, paying particular attention to older groups (aged 55+).
Fact sheet

Fact Check: Clive Palmer says hydroxychloroquine contributed to Australia's low COVID-19 death rate. Is he correct?


Businessman and former federal MP Clive Palmer claimed that use of the anti-malarial drug hydroxychloroquine contributed to Australia’s low death rate during the coronavirus pandemic. He said the Covid-19 death curve had flattened after the federal health minister announced the drug would be made available for hospital patients. Mr Palmer’s claim is baseless.